A Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) Injections in Adult Participants for Treatment of Glabellar Lines

Glabellar Lines Clinical Trial

Official title:

A Phase 1 Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) in Subjects for Treatment of Glabellar Lines

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05496335
• Other study ID #: M23-365
• Status: Completed
• Phase: Phase 1
• Start date: August 30, 2022
• Est. completion date: May 30, 2023

Study information

• Verified date: June 2023
• Source: AbbVie
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin. The purpose of this study is to assess how safe and effective sequential administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) is in adult participants with moderate to severe GL.

AGN-151586 is an investigational product being developed for the treatment of GL. Participants are placed in 1 of 2 groups, called treatment arms. Each group receives a different treatment. One group will receive AGN-151586 followed by BOTOX and the other group will receive placebo followed by BOTOX. There is a 1 in 2 chance that participants will be assigned to placebo. Around 80 adult participants with moderate to severe GL will be enrolled in the study in approximately 10 sites around the United States.

Participants will receive either AGN-151586 or Placebo administered as 5 intramuscular injections to the glabellar complex on Day 1. Eligible participants may then receive BOTOX injections on Day 30 and will be followed for up to 4 months.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 90
• Est. completion date: May 30, 2023
• Est. primary completion date: May 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Participants must be able to accurately assess their facial lines without the use of eyeglasses (contact lens use is acceptable).

• Participants with moderate or severe Glabellar Lines at maximum frown as assessed by both the investigator and participant using the Facial Wrinkle Scale (FWS) at screening and baseline (Day 1) visit.

Exclusion Criteria:

• Uncontrolled systemic disease.

• Presence or history of any medical condition that may place the participant at increased risk following exposure to AGN-151586 or BOTOX interfere with the study evaluation, including:

• Diagnosed myasthenia gravis, Lambert-Eaton syndrome, amyotrophic lateral sclerosis, or any other significant disease that might interfere with neuromuscular function

• History of facial nerve palsy

• Infection or dermatological condition at the treatment injection sites

• Marked facial asymmetry, dermatochalasis, deep dermal scarring, excessively thick sebaceous skin, excessively photodamaged skin, or the inability to substantially lessen facial lines even by physically spreading them apart

• Any eyebrow or eyelid ptosis at screening or Baseline Day 1 visit as determined by the investigator

• History of clinically significant drug, nicotine, or alcohol abuse within the last 6 months.

• Tattoos, jewelry, or clothing which obscure the glabellar area and cannot be removed.

• History of known immunization to any botulinum neurotoxin serotype.

• Anticipated need for surgery or overnight hospitalization during the study.

• History of surgical procedures on forehead and/or periorbital areas or affecting these areas including any lifting procedure (e.g., rhinoplasty, facial lift, suture lift, thread lift, brow lift, eyelid and/or eyebrow surgery).

• History of periorbital, mid-facial, or upper-facial treatment with semi permanent or permanent soft tissue fillers (e.g., poly-L-lactic acid, polyalkylimide, polymethylmethacrylate, polytetrafluoroethylene, and silicone), synthetic implantation and/or autologous fat transplantation.

• Known active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or participants with a positive polymerase chain reaction (PCR) test in the past 14 days prior to Baseline Day 1 who are asymptomatic.

• Participant who has been treated with any investigational drug within 30 days or 5 half-lives of the drug (whichever is longer) prior to the first dose of study drug or is currently enrolled in another clinical study or was previously enrolled in this study.

Related Conditions & MeSH terms

• Glabellar Lines

Intervention

Drug:
• AGN-151586
Intramuscular Injection
• BOTOX
Intramuscular Injection
• Placebo
Intramuscular Injection

Locations

Country	Name	City	State
United States	Bellaire Dermatology Associates /ID# 244428	Bellaire	Texas
United States	DeNova Research /ID# 244421	Chicago	Illinois
United States	Skin Research Institute LLC /ID# 244424	Coral Gables	Florida
United States	AboutSkin Research, LLC /ID# 244416	Greenwood Village	Colorado
United States	Laser and Skin Surgery Center of Indiana /ID# 244423	Indianapolis	Indiana
United States	Advanced Dermatology /ID# 244427	Lincolnshire	Illinois
United States	Skin and Cancer Associates, LLP /ID# 244415	Miami	Florida
United States	The Eye Research Foundation /ID# 244430	Newport Beach	California
United States	Cosmetic Laser Dermatology /ID# 244425	San Diego	California
United States	Premier Clinical Research /ID# 244429	Spokane	Washington

Sponsors (1)

Lead Sponsor	Collaborator
AbbVie

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants achieving "none" or "mild" on the Facial Wrinkle Scale (FWS) according to the investigator assessment of Glabellar Lines (GL) severity at maximum frown	The investigator assessment of GL severity at maximum frown using a 4-grade scale (0 to 3) where 0=none and 3=severe.	At Day 60